Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Taibang receives GMP certificate from SFDA
Taibang with the GMP certificate, expects to commence commercial manufacturing of FVIII products, which are used to treat hemophilia A. The subsidiary is also considering to construct an
Taibang with the GMP certificate, expects to commence commercial manufacturing of FVIII products, which are used to treat hemophilia A. The subsidiary is also considering to construct an
The 66,000ft² plant, which will increase the production capacity to more than double, will produce nutritional bars like MET-Rx, Pure Protein and Good ‘n Natural. NBTY CEO Jeff
Infusion Sciences Founder and Youth Infusion developer Budge Collinson said The Vitamin Shoppe is a better partner to carry Youth Infusion. "A huge part of the population has difficulty swallowing pills,"
The test uses Abbott’s proprietary fluorescence in situ hybridization (FISH) technology to detect rearrangements of the anaplastic lymphoma kinase (ALK) gene in advanced non-small cell lung cancer (NSCLC)
Fovista, an aptamer directed against platelet-derived growth factor subunit B (PDGF-B), regulates the cells associated with the walls of newly formed small blood vessels, the neovascular pericytes. The
The vaccine combined Immunovaccine’s DepoVax adjuvanting technology and Weill Cornell’s novel anti-cocaine vaccine (dAd5GNE). Immunovaccine chief science officer Dr. Marc Mansour said the company’s delivery system holds the
Under the agreement, AnGes will receive upfront payments, performance based milestone payments and payments after the product launch in accordance with its sales. AnGes president and CEO Ei
Pursuant to the three-year indefinite delivery/indefinite quantity contract, Cellectis will provide services such as generation of induced pluripotent stem (iPS) cell lines of research grade and differentiation of
Scilligence’s informatics products usage will enhance knowledge sharing and productivity of researchers in the discovery and development of small molecule and biologics therapeutics. In addition, Scilligence’s proprietary technology
The PK study assessed a single dose of one 2.4mg tablet or two tablets (4.8mg) of TNX-102 SL or the presently-marketed 5mg CBP tablet. The data revealed that